{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:14:38Z","timestamp":1753521278112,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction and hypothesis<\/jats:title>\n                <jats:p>TAS-303, which selectively inhibits noradrenaline reuptake, was developed for treating stress urinary incontinence (SUI). The proximal urethra mainly comprises smooth muscle fibers in which \u03b11 adrenergic receptors are abundant. This study was conducted to evaluate the effect of TAS-303 on urethral function and its safety profile in female patients with SUI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 16 women (age, 20\u201364 years) with SUI and\u2009&gt;\u20095.0\u00a0g of leakage in the 1-h pad test at screening were randomized and administered the assigned treatment in a double-blind manner. The primary end point was change in the maximal urethral closure pressure (MUCP) at 6\u00a0h post-dose. The secondary end point was change in the urethral closure pressure of the entire urethra and each urethral region (proximal, middle, and distal) at 6\u00a0h post-dose. The results were analyzed using a t-test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean change \u00b1 standard deviation in MUCP at 6\u00a0h post-dose was 3.473\u2009\u00b1\u200912.154 cmH<jats:sub>2<\/jats:sub>O for TAS-303 and 2.615\u2009\u00b1\u20099.794 cmH<jats:sub>2<\/jats:sub>O for placebo (between-group difference: 0.858 cmH<jats:sub>2<\/jats:sub>O, <jats:italic>P<\/jats:italic>\u2009=\u20090.8047). The mean changes \u00b1 standard deviation in urethral closure pressure of the proximal urethra at 6\u00a0h after the administration of TAS-303 18\u00a0mg and placebo were 3.863\u2009\u00b1\u200910.941 and 1.634\u2009\u00b1\u200912.093, respectively (between-group difference: 2.229 cmH<jats:sub>2<\/jats:sub>O, <jats:italic>P<\/jats:italic>\u2009=\u20090.5976).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>No significant difference in MUCP and urethral closure pressure was found between TAS-303 and placebo. However, the change in the proximal urethral closure pressure with TAS-303 was larger than that with placebo. This suggests that TAS-303 has pharmacological effects on urethral sphincteric function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00192-020-04470-7","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T08:05:21Z","timestamp":1596441921000},"page":"673-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TAS-303 effects on urethral sphincter function in women with stress urinary incontinence: phase I study"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-1395","authenticated-orcid":false,"given":"Makoto","family":"Yono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Irie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momokazu","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"unstructured":"The International Continence Society (ICS) glossary of terminology. https:\/\/www.ics.org\/glossary\/symptom\/stressurinaryincontinence. Accessed 24 Dec 2019.","key":"4470_CR1"},{"key":"4470_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2017.04.026","volume":"72","author":"F Fusco","year":"2017","unstructured":"Fusco F, Abdel-Fattah M, Chapple CR, Creta M, La Falce S, Waltregny D, et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral Tapes in the surgical treatment of female stress urinary incontinence. Eur Urol. 2017;72:567\u201391.","journal-title":"Eur Urol"},{"key":"4470_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1046\/j.1464-410X.2002.02963.x","volume":"90","author":"CH van der Vaart","year":"2002","unstructured":"van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 2002;90:544\u20139.","journal-title":"BJU Int"},{"key":"4470_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1046\/j.1464-410X.2003.04463.x","volume":"92","author":"KS Coyne","year":"2003","unstructured":"Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 2003;92:731\u20135.","journal-title":"BJU Int"},{"key":"4470_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2010.11.021","volume":"59","author":"JW Th\u00fcroff","year":"2011","unstructured":"Th\u00fcroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. EAU guidelines on urinary incontinence. Eur Urol. 2011;59:387\u2013400.","journal-title":"Eur Urol"},{"unstructured":"Burkhard FC, Bosch JL, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A, Amb\u00fchl D, Bedretdinova DA, Farag F, Lombardo R, Schneider MP (2019) EAU guidelines on urinary incontinence in adults. https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Urinary-Incontinence-2019.pdf","key":"4470_CR6"},{"key":"4470_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/luts.12111","volume":"8","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Takei M, Nishizawa O, Yamaguchi O, Kato K, Gotoh M, et al. Clinical guideline for female lower urinary tract symptoms. Low Urin Tract Symptoms. 2016;8:5\u201329.","journal-title":"Low Urin Tract Symptoms"},{"key":"4470_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1471-0528.2000.tb10407.x","volume":"107","author":"S M\u00f8rkved","year":"2000","unstructured":"M\u00f8rkved S, B\u00f8 K. Effect of postpartum pelvic floor muscle training in prevention and treatment of urinary incontinence: a one-year follow up. BJOG. 2000;107:1022\u20138.","journal-title":"BJOG"},{"unstructured":"Ozawa H (2008) Stress urinary incontinence. In: Kato K (Ed.) care for urinary incontinence and female urological diseases. Osaka: Medicus Shuppan, publishers co., pp 230\u2013231.","key":"4470_CR9"},{"key":"4470_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.118.248039","volume":"366","author":"H Mizutani","year":"2018","unstructured":"Mizutani H, Sakakibara F, Komuro M, Sasaki E. TAS-303, a novel selective norepinephrine reuptake inhibitor that increases urethral pressure in rats, indicating its potential as a therapeutic agent for stress urinary incontinence. J Pharmacol Exp Ther. 2018;366:322\u201331.","journal-title":"J Pharmacol Exp Ther"},{"unstructured":"European Medical Agency (2013) Guideline on the clinical investigation of medicinal products for the treatment of urinary Incontinence. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/07\/WC500146177.pdf. Accessed 24 Dec 2019.","key":"4470_CR11"},{"key":"4470_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/luts.12057","volume":"7","author":"M Yono","year":"2015","unstructured":"Yono M, Otani M, Ito K, Inoue Y, Furukawa K, Hori M, et al. Effect of duloxetine on urethral resting pressure and on sphincter contractility in response to coughing and magnetic stimulation in healthy women. Low Urin Tract Symptoms. 2015;7:93\u20138.","journal-title":"Low Urin Tract Symptoms"},{"key":"4470_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.eururo.2005.01.001","volume":"47","author":"I Karam","year":"2005","unstructured":"Karam I, Droupy S, Abd-Alsamad I, Uhl JF, Beno\u00eet G, Delmas V. Innervation of the female human urethral sphincter: 3D reconstruction of immunohistochemical studies in the fetus. Eur Urol. 2005;47:627\u201333.","journal-title":"Eur Urol"},{"key":"4470_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s001920200006","volume":"13","author":"C Pajoncini","year":"2002","unstructured":"Pajoncini C, Costantini E, Guercini F, Porena M. Intrinsic sphincter deficiency: do the maximum urethral closure pressure and the Valsalva leak-point pressure identify different pathogenic mechanisms? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:30\u20135.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"4470_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urol. 2003;61:37\u201349.","journal-title":"Urol"},{"doi-asserted-by":"publisher","unstructured":"Hanada R. Safety and pharmacokinetics of high-dose TAS-303 in healthy Japanese volunteers: a single-center, single-blind, randomized, placebo-controlled, parallel-group, multiple-ascending-dose study. Clin Pharmacol Drug Dev. 2020. https:\/\/doi.org\/10.1002\/cpdd.801.","key":"4470_CR16","DOI":"10.1002\/cpdd.801"},{"key":"4470_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1124\/dmd.108.023119","volume":"37","author":"W Kielbasa","year":"2009","unstructured":"Kielbasa W, Kalvass JC, Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos. 2009;37:137\u201342.","journal-title":"Drug Metab Dispos"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-020-04470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-020-04470-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-020-04470-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T23:53:12Z","timestamp":1633909992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-020-04470-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1007\/s00192-020-04470-7","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MG declares having received consultancy fees from Taiho, Astellas, Kowa, and Kyorin and grants from Taiho, Pfizer, Astellas, Daiichi Sankyo, Nihon Kayaku, Nippon Shinyaku, Takeda, and Asahikasei Pharma. All remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"International Continence Society, Florence, Italy, 12\u201315 September 2017.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conference presentations"}}]}}